What Is Lixte Biotechnology Holdings, I (LIXT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Lixte Biotechnology Holdings, I at its current price of $7.21. The composite intrinsic value is estimated at $4.53 (-37.1% average return), with 4 models flagging overvaluation risk. The most optimistic model, Sentiment SOTP, places fair value at $9.06 (+25.7%), while ML-RIV — the most conservative — estimates $0.06 (-99.1%). This +124.8% gap reflects genuine analytical uncertainty about Lixte Biotechnology Holdings, I's intrinsic worth.
What Do the Models Say About LIXT?
7 of 13 models are currently active for LIXT. Of these, 3 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates LIXT's intrinsic value at $2.13, implying -70.5% downside from the current price. See which stocks rank higher →
How Does LIXT Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, LIXT ranks #235 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Lixte Biotechnology Holdings, I competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is LIXT a Value Trap?
CirclFi's Value Trap algorithm assigns LIXT a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Lixte Biotechnology Holdings, I. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Lixte Biotechnology Holdings, I is rated at 4.8/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +124.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every LIXT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across LIXT's 7 active models, average confidence is 20%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad